These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 30865813)

  • 41. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
    Simchoni S; Friedman E; Kaufman B; Gershoni-Baruch R; Orr-Urtreger A; Kedar-Barnes I; Shiri-Sverdlov R; Dagan E; Tsabari S; Shohat M; Catane R; King MC; Lahad A; Levy-Lahad E
    Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3770-4. PubMed ID: 16537453
    [TBL] [Abstract][Full Text] [Related]  

  • 42. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
    Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inactivation of BRCA1 and BRCA2 in ovarian cancer.
    Hilton JL; Geisler JP; Rathe JA; Hattermann-Zogg MA; DeYoung B; Buller RE
    J Natl Cancer Inst; 2002 Sep; 94(18):1396-406. PubMed ID: 12237285
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.
    Jazaeri AA; Yee CJ; Sotiriou C; Brantley KR; Boyd J; Liu ET
    J Natl Cancer Inst; 2002 Jul; 94(13):990-1000. PubMed ID: 12096084
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population.
    Sekine M; Nagata H; Tsuji S; Hirai Y; Fujimoto S; Hatae M; Kobayashi I; Fujii T; Nagata I; Ushijima K; Obata K; Suzuki M; Yoshinaga M; Umesaki N; Satoh S; Enomoto T; Motoyama S; Tanaka K;
    Clin Cancer Res; 2001 Oct; 7(10):3144-50. PubMed ID: 11595708
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
    Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL
    J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Kwan E; Jack E; Vesprini DJ; Kuperstein G; Abrahamson JL; Fan I; Wong B; Narod SA
    Am J Hum Genet; 2001 Mar; 68(3):700-10. PubMed ID: 11179017
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A missense mutation in the BRCA2 gene in three siblings with ovarian cancer.
    Roth S; Kristo P; Auranen A; Shayehgi M; Seal S; Collins N; Barfoot R; Rahman N; Klemi PJ; Grénman S; Sarantaus L; Nevanlinna H; Butzow R; Ashworth A; Stratton MR; Aaltonen LA
    Br J Cancer; 1998 Apr; 77(8):1199-202. PubMed ID: 9579822
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
    Levy-Lahad E; Catane R; Eisenberg S; Kaufman B; Hornreich G; Lishinsky E; Shohat M; Weber BL; Beller U; Lahad A; Halle D
    Am J Hum Genet; 1997 May; 60(5):1059-67. PubMed ID: 9150153
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mutations of the BRCA2 gene in ovarian carcinomas.
    Takahashi H; Chiu HC; Bandera CA; Behbakht K; Liu PC; Couch FJ; Weber BL; LiVolsi VA; Furusato M; Rebane BA; Cardonick A; Benjamin I; Morgan MA; King SA; Mikuta JJ; Rubin SC; Boyd J
    Cancer Res; 1996 Jun; 56(12):2738-41. PubMed ID: 8665505
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
    Maxwell KN; Wubbenhorst B; Wenz BM; De Sloover D; Pluta J; Emery L; Barrett A; Kraya AA; Anastopoulos IN; Yu S; Jiang Y; Chen H; Zhang NR; Hackman N; D'Andrea K; Daber R; Morrissette JJD; Mitra N; Feldman M; Domchek SM; Nathanson KL
    Nat Commun; 2017 Aug; 8(1):319. PubMed ID: 28831036
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Germline mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma.
    Kim YT; Nam EJ; Yoon BS; Kim SW; Kim SH; Kim JH; Kim HK; Koo JS; Kim JW
    Gynecol Oncol; 2005 Dec; 99(3):585-90. PubMed ID: 16084575
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BRCA1 and BRCA2 sequence variations detected with next-generation sequencing in patients with premature ovarian insufficiency.
    Yılmaz NK; Karagin PH; Terzi YK; Kahyaoğlu İ; Yılmaz S; Erkaya S; Şahin Fİ
    J Turk Ger Gynecol Assoc; 2016; 17(2):77-82. PubMed ID: 27403073
    [TBL] [Abstract][Full Text] [Related]  

  • 54. AGO Austria recommendations for genetic testing of patients with ovarian cancer.
    Marth C; Hubalek M; Petru E; Polterauer S; Reinthaller A; Schauer C; Scholl-Firon T; Singer CF; Zschocke J; Zeimet AG
    Wien Klin Wochenschr; 2015 Aug; 127(15-16):652-4. PubMed ID: 26109557
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A case of ovarian carcinosarcoma with a germline pathogenic variant of BRCA2 involving a perforated appendix with an abscess.
    Saito A; Yamashita E; Sakurai U; Hirasawa A; Tanioka M; Tamura K; Umezawa S
    J Obstet Gynaecol Res; 2023 Oct; 49(10):2553-2557. PubMed ID: 37461372
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunohistochemistry for the detection of BRCA1 and BRCA2 proteins in patients with ovarian cancer: a systematic review.
    Teixeira LA; Candido Dos Reis FJ
    J Clin Pathol; 2020 Apr; 73(4):191-196. PubMed ID: 31719105
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families.
    Hartikainen JM; Kataja V; Pirskanen M; Arffman A; Ristonmaa U; Vahteristo P; Ryynänen M; Heinonen S; Kosma VM; Mannermaa A
    Clin Genet; 2007 Oct; 72(4):311-20. PubMed ID: 17850627
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The
    Du ZH; Xia Y; Yang Q; Gao S
    Technol Cancer Res Treat; 2020; 19():1533033820983289. PubMed ID: 33357097
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BRCA2 mutations in primary breast and ovarian cancers.
    Lancaster JM; Wooster R; Mangion J; Phelan CM; Cochran C; Gumbs C; Seal S; Barfoot R; Collins N; Bignell G; Patel S; Hamoudi R; Larsson C; Wiseman RW; Berchuck A; Iglehart JD; Marks JR; Ashworth A; Stratton MR; Futreal PA
    Nat Genet; 1996 Jun; 13(2):238-40. PubMed ID: 8640235
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The splicing factor SNRPB promotes ovarian cancer progression through regulating aberrant exon skipping of POLA1 and BRCA2.
    Li Y; Chen Z; Peng J; Yuan C; Yan S; Yang N; Li P; Kong B
    Oncogene; 2023 Jul; 42(31):2386-2401. PubMed ID: 37391593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.